Heparin Prophylaxis for Medical Patients?
Authors: Frank A. Lederle
Journal: Annals of Internal Medicine (1998)

Editorials1 May 1998Heparin Prophylaxis for Medical Patients?Frank A. Lederle, MDFrank A. Lederle, MDMinneapolis Veterans Affairs Medical Center; Minneapolis, MN 55417Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-9-199805010-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Pulmonary embolism causes or contributes to 200 000 deaths each year in the United States and is considered the most common preventable cause of hospital deaths [1]. Because the first manifestation of venous thromboembolism is often fatal pulmonary embolism and because most deaths occur within the first half hour, mortality is not sufficiently improved by therapy begun after diagnosis. Prophylactic measures against deep venous thrombosis and associated pulmonary embolism have therefore been advocated for many groups of hospitalized patients.Most studies and recommendations on prophylaxis of venous thromboembolism have involved low-dose heparin. It is available either in the standard unfractionated ...References1. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995; 108(4 Suppl):312S-334S. Google Scholar2. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990; 59:639-50. Google Scholar3. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The PRIME Study Group. Haemostasis. 1996; 26 Suppl 2:49-56. Google Scholar4. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis. 1996; 26:127-39. Google Scholar5. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996; 76:529-34. Google Scholar6. Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg. 1995; 169:567-71. Google Scholar7. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg. 1997; 84:750-9. Google Scholar8. Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 1997; 16:3-38. Google Scholar9. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988; 318:1162-73. Google Scholar10. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet. 1996; 347:1357-61. Google Scholar11. Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients [Letter]. Lancet. 1996; 348:205-6. Google Scholar12. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med. 1991; 115:591-5. Google Scholar13. Keane MG, Ingenito EP, Goldhaber SZ. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest. 1994; 106:13-4. Google Scholar14. Fernandez BB Jr, Mink AM, Grove MK. Venous thromboembolism prophylaxis, or lack of … [Letter]. Chest. 1995; 107:296. Google Scholar15. Lensing AW, Hirsh J. 125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost. 1993; 69:2-7. Google Scholar16. Flordal PA, Bergqvist D, Ljungstrom KG, Trngren S. Clinical relevance of the fibrinogen uptake test in patients undergoing elective general abdominal surgery-relation to major thromboembolism and mortality. Fragmin Multi-centre Study Group. Thromb Res. 1995; 80:491-7. Google Scholar17. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996; 313:652-9. Google Scholar18. Sandercock PA, van den Belt AG, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry. 1993; 56; 17-25. Google Scholar19. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997; 349:1569-81. Google Scholar20. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med. 1982; 96:561-5. Google Scholar21. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis. 1986; 16:159-64. Google Scholar22. Caulin C. The influence of CY 216 administration on hospital mortality of general medical in-patients: international collaborative double-blind study: methods and preliminary results. In: Breddin K, Fareed J, Samama M, eds. Fraxiparine: First International Symposium: Analytical and Structural Data, Pharmacology, Clinical Trials. Stuttgart: Schattauer; 1989:149-54. Google Scholar23. Graves EJ. National Hospital Discharge Survey: annual summary 1993. Vital Health Stat 13. 1995; 121:1-63. Google Scholar Author, Article, and Disclosure InformationAuthors: Frank A. Lederle, MDAffiliations: Minneapolis Veterans Affairs Medical Center; Minneapolis, MN 55417Corresponding Author: Frank A. Lederle, MD, Department of Medicine (III-0), Minneapolis Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBenefits and risks of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trialsEffectiveness and safety of thromboprophylaxis with enoxaparin in medical inpatientsPROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis planIncidence and Clinical Predictors of Deep Vein Thrombosis in Patients Hospitalized With Heart Failure in JapanRisque thromboembolique veineux au cours des affections médicales aiguës. Partie 2 : situations à risque en milieu ambulatoire, en milieu médical hospitalier et en médecine interneAnticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysisMeta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical PatientsFrancesco Dentali, MD, James D. Douketis, MD, Monica Gianni, MD, Wendy Lim, MD, and Mark A. Crowther, MD, MScCan Home Prophylaxis for Venous Thromboembolism Reduce Mortality Rates in Patients With Chronic Obstructive Pulmonary Disease?¿Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa?Venous ThrombosisThe Prophylaxis of Medical Patients for Thromboembolism Pilot StudyEfficacy of Unfractionated Heparin for Thromboembolism Prophylaxis in Medical PatientsAgreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practicesRisk factors for venous thromboembolismIncidence of Venous Thromboembolism in Hospitalized Patients vs Community ResidentsDecreased mortality after implementation of a treatment guideline for community-acquired pneumoniaDeep venous thrombosis prophylaxis in patients with heart diseasePrevention of Venous ThromboembolismNadroparin in the Prevention of Deep Vein Thrombosis in Acute Decompensated COPDTrombosis venosa profunda: presente y futuroAmélioration des pratiques de prévention de la maladie thromboembolique veineuse en milieu médical. Mission impossible? 1 May 1998Volume 128, Issue 9Page: 768-770KeywordsAspirinDeep vein thrombosisHeparinLow molecular weight heparinMortalityMyocardial infarctionProphylaxisPulmonary embolismRandomized trialsVenous thromboembolism ePublished: 15 August 2000 Issue Published: 1 May 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...